Critical appraisal of the role of ruxolitinib in myeloproliferative neoplasm-associated myelofibrosis

The recent approval of molecular-targeted therapies for myeloproliferative neoplasm-associated myelofibrosis (MPN-MF) has dramatically changed its therapeutic landscape. Ruxolitinib, a JAK1/JAK2 tyrosine kinase inhibitor, is now widely used for first- and second-line therapy in persons with MPN-MF,...

Descripción completa

Detalles Bibliográficos
Autores principales: Barosi, Giovanni, Rosti, Vittorio, Gale, Robert Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4445786/
https://www.ncbi.nlm.nih.gov/pubmed/26056473
http://dx.doi.org/10.2147/OTT.S31916

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4445786/
https://www.ncbi.nlm.nih.gov/pubmed/26056473
http://dx.doi.org/10.2147/OTT.S31916

Ejemplares similares